Disclosure Consultant: Smith & Nephew Stock: Johnson & - PowerPoint PPT Presentation

Nov 07, 2023 •192 likes •350 views

O rthopaedic Summit 2017: Evolving Techniques Las Vegas, Nevada USA Injections are Cost Effective: I inject everyone prior to any arthroscopy! Allston J. Stubbs, M.D., M.B.A. Medical Director Hip Arthroscopy & Associate Professor

O rthopaedic Summit 2017: Evolving Techniques Las Vegas, Nevada USA Injections are Cost Effective: I inject everyone prior to any arthroscopy! Allston J. Stubbs, M.D., M.B.A. Medical Director Hip Arthroscopy & Associate Professor Department of Orthopaedic Surgery December 5-9, 2017
Disclosure Consultant: Smith & Nephew • Stock: Johnson & Johnson • Research Support: Bauerfeind • Department-Division Support: Smith & Nephew, DePuy-Mitek, Arthex • Boards/Committees: AAOS, ABOS, AOSSM, ISHA, AANA, MASH, ISAKOS, Journal • of Hip Preservation Surgery
Do the Right Thing • Spike Lee Is more than a diagnostic tool, it’s a lifestyle
Plenty of Injection Champions • John Sekiya – AJR Am Journ Roentgenol 2012 • Thomas Byrd – Am J Sports Med 2004 • Carlos Guanche Combined over 50 years of experience!
Why Inject? • Diagnostic – Intraarticular vs Extraarticular – Organic vs Supratentorial – One needs a gold standard test: sensitivity and specificity – MRIs are now ~90% abnormal: high false positive rate • Therapeutic – Expanding options for treatment (not just steroids): local anesthetics, steroids, hyaluronic acid, PRP/ACP, Bone Marrow Aspirate, Amniotic – Patient Satisfaction: Improve treatment timeline – In office imaging: fluoroscopy, ultrasound, nanoscopy, open MRI
What’s the Success Rate of Hip Preservation Surgery? • ~80-85% Good to Excellent in the best of hands • Why not gain every percent you can for your patient?!
The Competition • If you don’t offer injection therapy, someone close to you will or not so close Turner & Knoepfler Cell Stem Cell June 2016
But I hate shots! Needle vs Knife
Winning Technique • Skin desensitization • 27G anesthetic • No pin cushion • Know osteology • Don’t over-fill • Instant cold pack technology • Proactive anti-inflammatory po
Limitations . . . • Time & Organization of work flow • Low wRVU • False negatives • Inflammatory response (Gadolinium worst offender especially with MRI-A) • Infection risk
Best time to initiate • Avoid MRI imaging within 6 weeks • Typically have imaging established before injections • Space out injections 4-6 weeks • Avoid intraarticular injections within 3 months of surgery [Wang Arthroscopy 2017]
Where to put them Our Favorites • Intracapsular • Iliopsoas bursa • Greater trochanteric bursa • Ischiofemoral space • Obturator internus muscle-tendon junction • Pudendal nerve • Lateral femoral cutaneous nerve
In Summary Don’t Left Be Holding the Bag • Make the best decision possible . . .based on injection management • Utilize technology • Inject every time!
Cool Future Hip Meetings Cancun May 2019 www.isakos.org Melbourne October 2018 www.isha.net

Recommend

Will You Have to Will You Have to Rat Yourself Rat Yourself Out? Out? New Self-Disclosure

Will You Have to Will You Have to Rat Yourself Rat Yourself Out? Out? New Self-Disclosure 60-day overpayment refund Risks for the Unwary Stark Self-Disclosure Protocol Transparency reports Due diligence Dan Mulholland

54 views • 4 slides

Disclosure Mark Ashley DAC Beachcroft LLP Disclosure: Overview A vast topic! What is

Disclosure Mark Ashley DAC Beachcroft LLP Disclosure: Overview A vast topic! What is disclosure? Why documents are really important How it works in practice: The request for records Letter of Claim Litigation Other

778 views • 26 slides

Disclosure I currently have no relationships of any kind with any company whose products or

Disclosure I currently have no relationships of any kind with any company whose products or services in any way relate to the practice of medicine, medical education or research. whose Disclosure In the interest of full disclosure, Dr. _____ (

226 views • 3 slides

4/14/2016 FINANCIAL DISCLOSURE FINANCIAL DISCLOSURE How Far Should We Go with the Endovascular

4/14/2016 FINANCIAL DISCLOSURE FINANCIAL DISCLOSURE How Far Should We Go with the Endovascular Treatment of Advanced PAD in the Era of Health Care Reform? An Endocompetent Vascular Surgeons View I Have No Financial Relationships to

179 views • 14 slides

The disclosure debate: to tell or not to tell? Lucy Blake Lecture Outline Aim: context and

The disclosure debate: to tell or not to tell? Lucy Blake Lecture Outline Aim: context and complexity 1. Disclosure in context: who uses reproductive donation, why is non-disclosure an issue? 2. History/ culture of disclosure: Roots of

461 views • 19 slides

Hallux Rigidus: 1 st MTP Fusion Technique What is the best construct ? Disclosure Disclosure

Hallux Rigidus: 1 st MTP Fusion Technique What is the best construct ? Disclosure Disclosure Consultant for: Extremity Medical Osteomed Crossroad Exactech BESPA Global Reviewer for : JBJS American JAAOS

606 views • 17 slides

DECLARATION OF CONFLICT OF INTEREST Disclosure: None Disclosure: None Independent study founded

DECLARATION OF CONFLICT OF INTEREST Disclosure: None Disclosure: None Independent study founded and performed within the Italian National Healthcare System. Approval by the relevant institutional ethical review boards, written informed

641 views • 21 slides

Forward-Looking Disclosure Forward-Looking Disclosure This information and other statements by

1 1 Forward-Looking Disclosure Forward-Looking Disclosure This information and other statements by the company may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to, among

401 views • 23 slides

Disclosure of tables Disclosure of statistical tables with primary and secondary suppressing of

Disclosure of tables Disclosure of statistical tables with primary and secondary suppressing of cell values within a SAS process chain Nordiskt SAS-mte, SSB, Oslo 2011 Anders Kraftling Methods Variety of methods to choose from in

668 views • 32 slides

SRI LANKA DEVELOPMENT UPDATE Public Disclosure Authorized MORE AND BETTER JOBS FOR AN UPPER

Public Disclosure Authorized SRI LANKA DEVELOPMENT UPDATE Public Disclosure Authorized MORE AND BETTER JOBS FOR AN UPPER MIDDLE-INCOME COUNTRY Public Disclosure Authorized www.worldbank.org/sldu June 2018 #SLDU2018 Public Disclosure

640 views • 28 slides

Overview and research directions Public Disclosure Authorized Dhushyanth Raju Office of the

Public Disclosure Authorized Public Disclosure Authorized Overview and research directions Public Disclosure Authorized Dhushyanth Raju Office of the Chief Economist, South Asia Region World Bank June 25, 2018 Public Disclosure Authorized

369 views • 22 slides

Disclosure

9th Annual UCSF Techniques in Complex Spine Surgery Course Disclosure

301 views • 17 slides

Relevant Financial Disclosure(s) <insert speaker name> Directions: 1) Insert your name

Relevant Financial Disclosure(s) <insert speaker name> Directions: 1) Insert your name above. 2) Choose the disclosure statement that reflects your disclosure status 3) Delete the other option and all RED text If NO relevant

205 views • 3 slides

I (and/or my coauthors) have something to disclose. Detailed disclosure information is

3/9/2018 Hip Case Presentations Travis G. Maak, MD Department of Orthopaedics Hip & Knee Preservation Service Disclosure I (and/or my coauthors) have something to disclose. Detailed disclosure information is available via: The

315 views • 12 slides

Open Disclosure: Policy Revision 2019 HSE | Open Disclosure Background Patients who are harmed

Open Disclosure: Policy Revision 2019 HSE | Open Disclosure Background Patients who are harmed as a result of their health care must be dealt with in an open, honest, empathic and timely manner. They must also receive a sincere and meaningful

281 views • 7 slides

9/14/2019 DISCLOSURE Faculty: Erin Michos, MD Aspirin in Primary CVD Prevention: DISCLOSURE: I

9/14/2019 DISCLOSURE Faculty: Erin Michos, MD Aspirin in Primary CVD Prevention: DISCLOSURE: I disclose that I have Is there any role in 2019? no relevant financial relationships with Erin D. Michos, MD, MHS, FACC, FAHA commercial interests

153 views • 14 slides

ERISA 401(k) Fee Litigation and New Fee Disclosure Regulations Strategies for Bringing and

Presenting a live 90 minute webinar with interactive Q&A ERISA 401(k) Fee Litigation and New Fee Disclosure Regulations Strategies for Bringing and Defending Fee Claims and Complying with DOL's Disclosure Requirements THURS DAY, DECEMBER

346 views • 32 slides

AANP Region X Update 2018 Disclosure and Objectives Disclosure: No industry conflicts to report

AANP Region X Update 2018 Disclosure and Objectives Disclosure: No industry conflicts to report Objectives: Identify purpose and initiatives of AANP and national policy priorities and activities Discuss legislative trends for Region X

644 views • 33 slides

Long Run Sustainability PFRDA Second Pension Conclave Public Disclosure Authorized 4 February

Public Disclosure Authorized Public Disclosure Authorized Expanding Coverage with Long Run Sustainability PFRDA Second Pension Conclave Public Disclosure Authorized 4 February 2016 William Price Senior Financial Sector Specialist World Bank

461 views • 20 slides

Texas Instruments & RFAB TI Information Selective Disclosure TI Information Selective

Texas Instruments & RFAB TI Information Selective Disclosure TI Information Selective Disclosure TI Information Selective Disclosure 2015 Corporate Citizenship Report Past 10 years Read more at TI.com/CCR TI Information

496 views • 13 slides

Venable SEC Update O C T O B E R 2 0 0 6 DEADLINES FOR COMPLIANCE WITH NEW DISCLOSURE RULES ON

Venable SEC Update O C T O B E R 2 0 0 6 DEADLINES FOR COMPLIANCE WITH NEW DISCLOSURE RULES ON EXECUTIVE AND DIRECTOR COMPENSATION RAPIDLY APPROACHING Begin Preparing for 10-K and Proxy Statement Disclosure Now New Form 8-K Rules in Effect

386 views • 4 slides

Surveillance Why ? What ? When ? How ? Dr C Fryer FRCPC) 1 Disclosure;

Surveillance Why ? What ? When ? How ? Dr C Fryer FRCPC) 1 Disclosure; Disclosure; None. I have no conflicts. I have no industry financial relationships. Background: Background: Relapse is the

568 views • 9 slides

Beijing Mines and Money 2012 Investor Presentation Disclosure Statement Disclosure Statement

Beijing Mines and Money 2012 Investor Presentation Disclosure Statement Disclosure Statement Audalia Resources Limited (Audalia) has prepared this presentation based on information available to it. No representation or warranty

423 views • 29 slides

Company Presentation Jefferies Healthcare Conference, London November 2014 Important Disclosure

Company Presentation Jefferies Healthcare Conference, London November 2014 Important Disclosure Important Disclosure Important Disclosure Important Disclosure Materials and information provided during this presentation may contain

249 views • 24 slides